Sydney student solves piece of the diabetes puzzle



Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc., U.S., announced today that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended that the FDA approve febuxostat for the treatment of hyperuricemia in patients with gout. The vote was 12 to zero in favor of

Full Post: Febuxostat recommended by panel for treatment of hyperuricemia in patients with gout

An important piece in the diabetes puzzle which has perplexed scientists for decades has been uncovered by a Sydney PhD student at Sydney’s Garvan Institute of Medical Research.

The novel finding by Freddy Yip has revealed how insulin works and brings researchers one step nearer to understanding just how insulin prompts fat and muscle cells to absorb glucose.

Professor David James, head of Garvan’s Diabetes Program says ever since the 1920s, when Banting and Best discovered insulin, scientists have been struggling to discover how insulin actually works and now Freddy Yip has unveiled a completely novel action of insulin which plays a fundamental role in glucose uptake - a process that is defective in type 2 diabetes.

In type 2 diabetes two processes are involved - insufficient production of insulin in the pancreas after a meal and the faulty uptake and storage of glucose in fat and muscle cells, or ‘insulin resistance’.

Professor James says Freddy’s finding focuses on the intersection between these two processes.

Freddy Yip says in the cell there are a series of motor proteins that have the ability to move other molecules from one place to another along intracellular rail road tracks and he discovered that insulin activates a specific kind of motor protein known as Myo1c, which in turn performs a critical role in glucose uptake.

Insulin controls glucose uptake into the body’s fat cells by moving glucose transporter proteins from inside the cell to the surface membrane so that they can pump glucose into the cell and Myo1c aids in this process by helping the transporters slide into the surface membrane.

In healthy people, around 80% of the glucose transporters migrate to the cell membrane after a meal, allowing plenty of glucose into the cell but in people with Type 2 diabetes, that figure drops to around 10%.

Freddy Yip says it was already known that Myo1c was somehow involved in the regulation of glucose transport but his research indicates that Myo1c is a major target of insulin action and helps to accelerate the delivery of transporters to the membrane.

He believes there may be blockages in the signal between insulin and myo1c in people who develop insulin resistance and if he is correct, it should be possible to target that pathway for development of new therapies.

Professor James says the finding is a welcome milestone on a very long road of discovery and while they are not saying they have found a way to cure diabetes,they have found a pretty significant clue.

Freddy Yip believes his study will create a strong foundation for future diabetes research.

His research is published online in the prestigious international journal, Cell Metabolism.

Link




One of the most reliable indicators to predict that a person will develop type 2 diabetes is the presence of insulin resistance. Insulin is produced in the pancreas and is the hormone responsible for ensuring that glucose reaches several tissues and organs in the body, such as muscles. Insulin resistance is characterized by the lack

Full Post: More data released on key diabetes genes



A drug based on a chemical found in garlic can treat diabetes types I and II when taken as a tablet, a study in the new Royal Society of Chemistry journal Metallomics says. When Hiromu Sakurai and colleagues from the Suzuka University of Medical Science, Japan, gave the drug orally to type I diabetic mice,

Full Post: Garlic drug treats diabetes



Singapore researchers have developed an unlimited number of pure insulin-producing cells from mouse embryonic stem cells (ESCs). These pure insulin-producing cells, which according to electron microscopy studies, have the same sub-cellular structures as the insulin-producing cells naturally found in the pancreas, were highly effective in treating diabetes in the mouse model. The transplants of pure

Full Post: Scientists develop unlimited pure insulin-producing cells from mouse embryonic stem cells



A benchmarking study published in the Journal of Hospital Medicine evaluated contemporary hospital glycemic management in United States academic medical centers, determining glucose control practices are suboptimal and do not meet current American Diabetes Association (ADA) hospital diabetes care standards. The retrospective cohort study was based upon a 2005 collaborative project by The University HealthSystem

Full Post: Hospital diabetes care standards not met by US academic medical centers



In a finding that could significantly influence the way type 1 diabetes is treated, researchers at Albert Einstein College of Medicine of Yeshiva University have developed a technique for transplanting insulin-producing pancreatic cells that causes only a minimal immune response in recipients. At present, cell transplantation therapy is limited because transplant recipients are forced to

Full Post: Researchers engineer pancreatic cell transplants to evade immune response